newsfilter
← Latest News
GlobeNewswire·

Angion Provides Corporate Update and Reports Full Year 2021 Financial Results

-- Enrollment continues in Phase 2 JUNIPER trial of ANG-3070 for the treatment of patients with primary proteinuric kidney diseases -- Ended the year with nearly $89M in cash and cash equivalents UNIONDALE, N.Y., March 30, 2022 (GLOBE NEWSWIR